SCHEMBL722440

SCHEMBL722440

COc1cc(-c2cc3nccc(-c4ccc(CO)nc4)c3o2)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 3/20 0.43
FYN P06241 6/20 0.41
CHEK2 O96017 2/20 0.40
PTGES O14684 1/20 0.39
ALOX5 P09917 1/20 0.39
BRD4 O60885 1/20 0.38
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
TGFBR1 P36897 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
CALCRL Q16602 1/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP1B1 Q16678 1/20 0.37
GAK O14976 1/20 0.37
S1PR1 P21453 1/20 0.37
SYK P43405 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210592 0.86 PDE4C (0.45) PDE4CFYNCHEK2BRD4JAK2
SCHEMBL725087 0.86 FYN (0.53) PDE4CFYNCHEK2BRD4JAK2
SCHEMBL723093 0.85 PDE4C (0.55) PDE4CFYNPTGESALOX5BRD4
SCHEMBL16638610 0.84 PDE4C (0.47) PDE4CPTGESALOX5BRD4JAK2
SCHEMBL722937 0.83 FYN (0.48) PDE4CFYNCHEK2PTGESALOX5
SCHEMBL722839 0.83 PDE4C (0.51) PDE4CFYNPTGESALOX5BRD4
SCHEMBL721309 0.83 PDE4C (0.47) PDE4CFYNPTGESALOX5BRD4
SCHEMBL722753 0.82 NEK2 (0.47) PDE4CFYNPTGESALOX5JAK2
SCHEMBL15210488 0.81 PDE4C (0.45) PDE4CFYNBRD4JAK2JAK1
SCHEMBL10267299 0.81 MAPK1 (0.55) PDE4CBRD4ALDH1A1CYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885FYN 33/4885CHEK2 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.